MO8833A_supplementary_materials_v2_Figures.pdf (646.42 kB)
Supplementary Figures – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer
figure
posted on 2022-01-25, 09:05 authored by Figshare Future Science GroupFigshare Future Science Group, Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi|
Figure S1 Kaplan–Meier curves before matching adjustment for a) overall survival b) progression-free survival
Figure S2 Forest plot of pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS 1–49% and ≥50%a |
